RayKnowChina Research Map
Shortlist

Not yet recruitingLung cancerPhase not stated

Registered title, quoted from ClinicalTrials.gov

Diagnostic Performance of an AI-Based Multi-Omics Model for Early Lung Cancer

An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Beijing Chao-Yang Hospital; 4 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 5

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorBeijing Chao-Yang Hospital首都医科大学附属北京朝阳医院BeijingHospital page
  2. Study siteBeijing Friendship Hospital首都医科大学附属北京友谊医院BeijingHospital page
  3. Study sitePeking University Cancer Hospital北京大学肿瘤医院BeijingHospital page
  4. Study sitePeking University Third Hospital北京大学第三医院BeijingHospital page
  5. Study siteThird Xiangya Hospital中南大学湘雅三医院ChangshaHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07882628, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Pathological/clinical diagnosis: Definitive pathological diagnosis after surgical resection is required as the gold standard.

    Inclusion criterion 6

    Performance status: Able to tolerate bronchoscopic biopsy, with no contraindications to biopsy.

    Inclusion criterion 10

    Nodule characteristics: Single or multiple pulmonary nodules detected on thin-section CT (slice thickness ≤1.5 mm). The target lesion planned for biopsy has a maximum diameter ≥8 mm and ≤30 mm.

    Inclusion criterion 11

    Clinician assessment: Clinicians recommend bronchoscopic biopsy (including conventional bronchoscopy, endobronchial ultrasound [EBUS], navigational bronchoscopy, etc.) to determine the pathological nature of the pulmonary nodule.

    Inclusion criterion 12

    Specimen and imaging: Small tissue specimens obtained during biopsy undergo three-dimensional interferometric imaging, and complete imaging data are retained.

    Inclusion criterion 13

    Pathological/clinical diagnosis: Definitive pathological diagnosis of the small biopsy specimen is required as the gold standard.

    Inclusion criterion 14

  3. Prior anti-tumor treatment: Any form of anti-tumor therapy received within the past 6 months, including chemotherapy, radiotherapy, targeted therapy, or immune checkpoint inhibitor therapy.

    Exclusion criterion 3

    Prior anti-tumor treatment: Any form of anti-tumor therapy received within the past 6 months, including chemotherapy, radiotherapy, targeted therapy, or immune checkpoint inhibitor therapy.

    Exclusion criterion 11

  4. Performance status: Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.

    Inclusion criterion 2

  5. Nodule characteristics: Single or multiple pulmonary nodules detected on thin-section CT (slice thickness ≤1.5 mm). The largest diameter of the primary lesion is ≥8 mm and ≤20 mm. For patients with multiple nodules, the maximum diameter of other lesions must be <8 mm.

    Inclusion criterion 3

  6. Other malignant tumors: History of other malignant tumors within the past 3 years.

    Exclusion criterion 5

  7. Special population: Pregnant or breastfeeding women.

    Exclusion criterion 7

    Special population: Pregnant or breastfeeding women.

    Exclusion criterion 12

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07882628, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

Sub-study 1:

  • Age: 18-75 years.
  • Performance status: Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
  • Nodule characteristics: Single or multiple pulmonary nodules detected on thin-section CT (slice thickness ≤1.5 mm). The largest diameter of the primary lesion is ≥8 mm and ≤20 mm. For patients with multiple nodules, the maximum diameter of other lesions must be <8 mm.
  • No clinical or imaging evidence of lymph node or distant metastasis.
  • Planned surgical resection: Patients with complete clinical data and preoperative thin-section CT; peripheral blood samples can be collected.
  • Pathological/clinical diagnosis: Definitive pathological diagnosis after surgical resection is required as the gold standard.
  • Informed consent: Patients voluntarily join this study, sign written informed consent, and agree to complete scheduled follow-up for at least 5 years.
  • Sample availability: Patients can provide sufficient peripheral blood samples as required by the study protocol. For patients undergoing surgery or biopsy, tumor tissues and adjacent normal tissue samples meeting quality requirements can be obtained.

Sub-study 2:

  • Age: 18-75 years.
  • Performance status: Able to tolerate bronchoscopic biopsy, with no contraindications to biopsy.
  • Nodule characteristics: Single or multiple pulmonary nodules detected on thin-section CT (slice thickness ≤1.5 mm). The target lesion planned for biopsy has a maximum diameter ≥8 mm and ≤30 mm.
  • Clinician assessment: Clinicians recommend bronchoscopic biopsy (including conventional bronchoscopy, endobronchial ultrasound [EBUS], navigational bronchoscopy, etc.) to determine the pathological nature of the pulmonary nodule.
  • Specimen and imaging: Small tissue specimens obtained during biopsy undergo three-dimensional interferometric imaging, and complete imaging data are retained.
  • Pathological/clinical diagnosis: Definitive pathological diagnosis of the small biopsy specimen is required as the gold standard.
  • Informed consent: Patients voluntarily join this study, sign written informed consent, and agree to complete scheduled follow-up for at least 5 years.

Exclusion Criteria:

Sub-study 1:

  • Concurrent immune diseases: Active autoimmune diseases (such as rheumatoid arthritis, systemic lupus erythematosus, etc.), or patients receiving long-term systemic immunosuppressants or glucocorticoids within the past 6 months.
  • Active infection: Active infections (such as active pulmonary tuberculosis, acute phase of SARS-CoV-2 infection, etc.) that may significantly affect immune status.
  • Prior anti-tumor treatment: Any form of anti-tumor therapy received within the past 6 months, including chemotherapy, radiotherapy, targeted therapy, or immune checkpoint inhibitor therapy.
  • Suspected multiple primary lung cancers where secondary lesions require simultaneous or staged intervention (surgery, ablation, radiotherapy, etc.).
  • Other malignant tumors: History of other malignant tumors within the past 3 years.
  • Severe dysfunction of major organs: Severe hepatic or renal insufficiency (judged by investigators).
  • Special population: Pregnant or breastfeeding women.
  • Poor study compliance: Any psychological, family, or social factors that prevent patients from understanding and following the study protocol and follow-up plan.

Sub-study 2:

  • Concurrent immune diseases: Active autoimmune diseases (such as rheumatoid arthritis, systemic lupus erythematosus, etc.), or patients receiving long-term systemic immunosuppressants or glucocorticoids within the past 6 months.
  • Active infection: Active infections (such as active pulmonary tuberculosis, acute phase of SARS-CoV-2 infection, etc.) that may significantly affect immune status.
  • Prior anti-tumor treatment: Any form of anti-tumor therapy received within the past 6 months, including chemotherapy, radiotherapy, targeted therapy, or immune checkpoint inhibitor therapy.
  • Special population: Pregnant or breastfeeding women.
  • Poor compliance with study or procedure: Any physical, psychological, family, or social factors that prevent patients from understanding and following the study protocol or tolerating bronchoscopy.
  • Bleeding tendency or severe coagulation disorders.

Quoted from ClinicalTrials.gov, NCT07882628, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07882628, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07882628